ATHENS, Ga. & LOS GATOS, Calif.–(BUSINESS WIRE)–Oct 25, 2023– Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing PIV5-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, announced the publication of positive Phase 1 clinical trial results of its intranasal RSV…Read More
Positive Phase 1 Data for Blue Lake Biotechnologys Intranasal RSV Vaccine Published in Science Advances
